行业近况心通医疗关联企业4C Medical完成D轮融资(波士顿科学领投),中国相关瓣膜资产交易事件频发;中国瓣膜手术量呈现良好增长态势。评论中国相关瓣膜资产近期屡获MNC投资。1)心通医疗此前投资的创新公司4C Medical近期宣布完成1.75 亿美元的D轮融资1,由波士顿科学领投。4C公司聚焦于经导管二尖瓣置换(TMVR)治疗领域,其核心产品AltaValve于2024 年内获得美国FDA...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.